Cyclacel Pharmaceuticals (NASDAQ:BGMS) Releases Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) issued its quarterly earnings data on Friday. The company reported ($0.04) earnings per share for the quarter, Zacks reports.

Cyclacel Pharmaceuticals Stock Performance

BGMS opened at $1.00 on Friday. Cyclacel Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $34.65. The stock’s 50-day moving average is $0.99. The firm has a market cap of $5.50 million, a P/E ratio of -0.22 and a beta of -0.49.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cyclacel Pharmaceuticals presently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.